Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584468 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1RAB9AKMT2APOLB | |
| SCHEMBL8017456 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9AMAOBPOLBTDP1 | |
| SCHEMBL2117441 | 0.84 | ALOX15 (0.50) | SMN1; SMN2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL1283871 | 0.83 | SMN1; SMN2 (1.00) | SMN1; SMN2MEN1RAB9AKMT2ANR4A2 | |
| SCHEMBL8219820 | 0.83 | SMN1; SMN2 (0.73) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL9220908 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2MEN1KMT2ACYP3A4HIF1A | |
| SCHEMBL6153890 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL733369 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| SCHEMBL12622683 | 0.81 | SMN1; SMN2 (0.71) | SMN1; SMN2MEN1RAB9AKMT2AMAOB | |
| Hydrochloric Acid SCHEMBL4640626 | 0.81 | SMN1; SMN2 (0.96) | SMN1; SMN2MEN1RAB9AKMT2ANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924393-A | Monomer of 3' -mercapto nucleoside analogue and its synthesis process | 天津兴博润生物制药有限公司 | 2024-04-26 | — | — | CN | claimed |
| US-20250134871-A1 | UPR MODULATORS TO TREAT HEARING LOSS | JACARANDA BIOSCIENCES, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-118206525-A | Aromatic ring [ d ] thiazepine ketone compound and preparation method thereof | 北京化工大学 | 2024-06-18 | — | — | CN | disclosed |
| CN-117924393-A | Monomer of 3' -mercapto nucleoside analogue and its synthesis process | 天津兴博润生物制药有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2023114451-A1 | UPR MODULATORS TO TREAT HEARING LOSS | JACARANDA BIOSCIENCES, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2021-07-08 | — | — | US | disclosed |
| EP-3727401-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| WO-2004071507-A1 | TETRACYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-08-26 | — | — | WO | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| CN-1486302-A | Substituted 1,3, 5-triazines and pyrimidines as ABCA-1 potentiating compounds against coronary artery disease or arteriosclerosis | CV���ƹ�˾ | 2004-03-31 | — | — | CN | disclosed |
| EP-1341773-A2 | SUBSTITUTED 1,3,5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002046172-A2 | SUBSTITUTED 1, 3, 5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-5139564-A | Applying postemergence | PARK SANG W (KR) | 1992-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | PSMB3, PSME3, PSMD3 | SMN1; SMN2 3198/4885MEN1 3763/4885RAB9A 3319/4885 |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | SMN1; SMN2 2211/4885MEN1 4329/4885RAB9A 3814/4885 |
| US-20210206796-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | SMN1; SMN2 2942/4885MEN1 1913/4885RAB9A 643/4885 |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K1, MAP3K15 | SMN1; SMN2 1988/4885MEN1 1149/4885RAB9A 2105/4885 |
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | SMN1; SMN2 4558/4885MEN1 4471/4885RAB9A 2138/4885 |
| US-20250134871-A1 | UPR MODULATORS TO TREAT HEARING LOSS | ATF4, XBP1, ATF1 | SMN1; SMN2 2721/4885MEN1 4567/4885RAB9A 3875/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | SMN1; SMN2 3101/4885MEN1 1971/4885RAB9A 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.